ArticlePharmacology research & perspectives2024

Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.

Jia Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.